Evidence map›Paper›PMID 42653267›Full record

ReviewInternational journal of molecular sciences2026

Putative Modulation of OATP1A2 and P-gp Expression at the Blood-Brain Barrier by Nrf2-PXR: An Associative Hypothesis for Amyloid-β Transport in Alzheimer's Disease.

Lin Li, Yu Zhang, Sihong Li, Menghua Zhao, Weiqiang Hu, Yuwei Xiao, Jinhua Wen

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lin LiSchool of Pharmacy, Nanchang University, Nanchang 330006, China.
Yu ZhangSchool of Pharmacy, Nanchang University, Nanchang 330006, China.
Sihong LiSchool of Pharmacy, Nanchang University, Nanchang 330006, China.
Menghua ZhaoDepartment of GCP, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Weiqiang HuDepartment of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Yuwei XiaoSchool of Pharmacy, Nanchang University, Nanchang 330006, China.
Jinhua WenDepartment of GCP, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.

Funding

National Natural Science Foundation of China 82360734
6 · The paper itself

Abstract

Impaired amyloid-β (Aβ) clearance across the blood-brain barrier (BBB) is a major contributor to Aβ accumulation in Alzheimer's disease (AD). P-glycoprotein (P-gp) has been identified as a key BBB efflux transporter involved in Aβ clearance, whereas emerging evidence suggests that organic anion transporting polypeptide 1A2 (OATP1A2) and its rodent counterparts, such as Oatp1a4, may participate in the influx component of Aβ transport. Nuclear factor erythroid 2-related factor 2 (Nrf2) and pregnane X receptor (PXR) are important transcriptional regulators of oxidative stress responses, xenobiotic metabolism, and transporter expression and may therefore modulate OATP1A2 and P-gp expression at the BBB. However, the mechanisms by which Nrf2-PXR crosstalk may regulate OATP1A2/P-gp expression in BBB endothelial cells under AD-relevant pathological conditions, as well as the consequences of this regulation for Aβ transport homeostasis, remain incompletely understood. This review summarizes current evidence linking P-gp, OATP1A2/Oatp1a4, Nrf2, and PXR to BBB transporter homeostasis in AD. A "net-effect" model is further proposed, in which Nrf2-PXR crosstalk may shift the BBB transporter balance toward enhanced P-gp-mediated efflux and reduced OATP1A2-associated influx. Because several key components of this model, particularly OATP1A2-mediated Aβ influx and BBB-specific Nrf2-PXR regulation, remain insufficiently validated, this model should be regarded as a mechanistic framework for future experimental investigation rather than as an established pathogenic pathway. Clarifying this regulatory axis may provide new insights into BBB dysfunction and impaired Aβ clearance in AD and may help identify potential molecular targets for therapeutic intervention.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesATP Binding Cassette Transporter, Subfamily B, Member 1Blood-Brain BarrierNF-E2-Related Factor 2Organic Anion TransportersPregnane X ReceptorAnimalsBiological TransportGene Expression RegulationHumansAmyloid beta-PeptidesATP Binding Cassette Transporter, Subfamily B, Member 1NF-E2-Related Factor 2Organic Anion TransportersPregnane X ReceptorSLCO1A2 protein, humanAlzheimer’s diseaseblood–brain barriercrosstalkNrf2OATP1A2P-glycoproteinPXR

Identifiers

PMID42653267
PMCPMC13513854

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.